AT-37 PHASE I STUDY OF PLERIXAFOR AND BEVACIZUMAB IN RECURRENT HIGH-GRADE GLIOMA

Although anti-angiogenic therapy for high-grade glioma is promising, responses are not durable. The SDF-1/CXCR4 axis may help mediate resistance to VEGFR inhibition. Plerixafor is a reversible CXCR4 inhibitor that has demonstrated growth inhibition in glioblastoma xenografts. We conducted a Phase I...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Lee, Eudocia, Smith, Katrina, Muzikansky, Alona, Gerstner, Elizabeth, Kuhn, John, Reardon, David, Nayak, Lakshmi, Norden, Andrew, Rifenburg, Jennifer, Pulverenti, Julee, Stokes, Deirdre, Lam, Priscilla, Martins, Tiago, Hempfling, Kelly, McCluskey, Christine, Gaffey, Sarah, Batchelor, Tracy, Duda, Dan, Jain, Rakesh, Wen, Patrick
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2014
Gaiak:
Abstracts
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4217816/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nou237.37
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak